Types of SNs
| PTLD . | N = 145 . |
|---|---|
| Early PTLD | 130 |
| Late PTLD | 15 |
| AL/MDS | N = 23 |
| ALL | 3 |
| AML | 12 |
| Donor-derived AML | 3 |
| MDS | 5 |
| STs | N = 72∗ |
| Lung | 10 |
| Thyroid | 8 |
| Bone sarcoma | 1 |
| Soft tissue sarcoma | 6 |
| Oral cavity | 3 |
| Upper GI | 2 |
| Colorectal | 3 |
| Skin (BCC) | 4 |
| Skin (non-BCC) | 4 |
| Breast | 3 |
| Cervix | 2 |
| Kidney | 2 |
| Bladder | 2 |
| CNS | 1 |
| Neuroendocrine | 1 |
| Pancreas | 1 |
| Parotide | 1 |
| Prostate | 1 |
| Other ST | 3 |
| Breast + skin (BCC) | 1 + 1 |
| Breast + skin (non-BCC) | 1 + 1 |
| Lung + skin (BCC) | 1 + 1 |
| Thyroid + bone sarcoma | 1 + 1 |
| CNS+ colorectal | 1 + 1 |
| Upper GI + CNS | 1 + 1 |
| Neuroendocrine + skin (BCC) | 1 + 1 |
| PTLD . | N = 145 . |
|---|---|
| Early PTLD | 130 |
| Late PTLD | 15 |
| AL/MDS | N = 23 |
| ALL | 3 |
| AML | 12 |
| Donor-derived AML | 3 |
| MDS | 5 |
| STs | N = 72∗ |
| Lung | 10 |
| Thyroid | 8 |
| Bone sarcoma | 1 |
| Soft tissue sarcoma | 6 |
| Oral cavity | 3 |
| Upper GI | 2 |
| Colorectal | 3 |
| Skin (BCC) | 4 |
| Skin (non-BCC) | 4 |
| Breast | 3 |
| Cervix | 2 |
| Kidney | 2 |
| Bladder | 2 |
| CNS | 1 |
| Neuroendocrine | 1 |
| Pancreas | 1 |
| Parotide | 1 |
| Prostate | 1 |
| Other ST | 3 |
| Breast + skin (BCC) | 1 + 1 |
| Breast + skin (non-BCC) | 1 + 1 |
| Lung + skin (BCC) | 1 + 1 |
| Thyroid + bone sarcoma | 1 + 1 |
| CNS+ colorectal | 1 + 1 |
| Upper GI + CNS | 1 + 1 |
| Neuroendocrine + skin (BCC) | 1 + 1 |
BCC, basal cell carcinoma; CNS, central nervous system.
Seven patients developed 2 STs, which corresponded to a total of 72 ST reported.